TCN Prime, a medical device developer, Successfully Raises 240 Million JPYEN in Series A Funding

TCN Prime Corporation (Bunkyo-ku, Tokyo; CEO: Akihide Konishi; "TCNP") has successfully raised 240 million yen in a Series A round of financing. The third-party allotment was made to Medical Development Support No. 2 Investment Limited Partnership, a venture fund specializing in the medical device field, managed by RMD Partners Tokyo Inc.

TCN Prime

TCNP is a Kobe University-approved venture company established in October 2023 based on the research results of cardiologists Akihide Konishi and Masamichi Iwasaki with the cooperation of Neuroceuticals, Inc., a medical device development start-up company support organization. Currently, we are developing two types of medical devices for cardiac diseases: one is a balloon catheter system for DIVE (diastolic aortic valve dilation) and the other is a new ECMO catheter for ECMO (extracorporeal circulation using an artificial lung and pump). Both of these devices are designed to meet unmet clinical needs in the field of cardiovascular medicine, and we aim to implement them in society as soon as possible. The company is a start-up company that is striving to develop new medical devices that are less burdensome to patients and trusted by medical professionals.

Background of the Fundraising

TCNP is developing two medical devices, each of which has passed the initial stage of development and is in the process of being developed into a final product to be brought into clinical trials. In this context, medical devices need to be developed in a step-by-step process to obtain regulatory approval. Especially for the balloon catheter system for DIVE (diastolic aortic valve dilation), we are developing the catheter as well as the driving machine at the same time. The funds raised will be used for the design freeze, prototype verification, and preparation for mass production of the DIVE system.

About DIVE

DIVE (Diastolic Inflation for Valvular Expansion) is a new treatment methodology that TCNP is trying to establish for severe aortic stenosis, a serious disease with a poor prognosis. Although BAV and TAVI treatment methods have been developed so far, TCNP is now expanding its use to patients who do not fit into these treatment methods. The features of this therapy include synchronized electrocardiographic valve dilation without high-frequency pacing, which we believe is safer and more reliable than BAV.

■Company Profile

TCN Prime Corporation

Establishment : October 6, 2023

Business description: Development and sales of medical devices

Head Office: NCI Incubator, 1-28-10 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

Representative Director : Akihide Konishi

HP ： https://www.tcn-prime.jp/